SDZ-RAD |
AFINITOR DISPERZ |
ZORTRESS |
RAD001 |
RAD 666 |
RAD-666 |
AFINITOR |
CERTICAN |
RAD-001 |
VOTUBIA |
EVEROLIMUS |
42-O-(2-HYDROXYETHYL)RAPAMYCIN |
40-O-(2-HYDROXYETHYL)-RAPAMYCIN |
chembl:CHEMBL1908360 |
rxcui:141704 |
drugbank:01590 |
chemidplus:159351-69-6 |
pubchem.compound:6442177 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | immunosuppressant |
FDA Approval | Pancreatic, gastrointestinal, or lung origin neuroendocrine tumors; Renal cell carcinoma, Subependymal giant cell astrocytoma associated with tuberous sclerosis, Breast cancer (ER+, HER2-) |
Notes | rapalogue |
Drug Class | Kinase Inhibitors |
Drug Class | immunosuppressive agents |
Year of Approval | 2009 |
inhibitor (inhibitory) |
Mechanism of Interaction | FK506-binding protein 1A inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | case report |
n/a |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Phase Ib/II |
Response Type | sensitive |
RAD001 | Development Name |
EVEROLIMUS | Generic Name |
AFINITOR | Trade Name |
Drug Class | Kinase Inhibitors |
Notes | rapalogue |
FDA Approval | Pancreatic, gastrointestinal, or lung origin neuroendocrine tumors; Renal cell carcinoma, Subependymal giant cell astrocytoma associated with tuberous sclerosis, Breast cancer (ER+, HER2-) |
EVEROLIMUS | Primary Drug Name |
Year of Approval | 2009 |
Drug Class | immunosuppressive agents |
Drug Indications | immunosuppressant |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL1908360 | ChEMBL Drug ID |
EVEROLIMUS | Primary Drug Name |
EVEROLIMUS | Drug Generic Name |
AFINITOR | Drug Trade Name |
D0K3QS | TTD Drug ID |